Just caught Iovance's latest update and the market's clearly impressed with what they're showing. Stock jumped over 25% on the back of some meaningful clinical progress in sarcoma treatment, which honestly feels like a bigger deal than the initial price action might suggest.

So here's what caught my attention: their Lifileucel therapy is posting a 50% response rate in a pilot study for advanced soft tissue sarcoma cases—specifically undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma. These are patients with pretty brutal disease profiles, heavily pretreated, so a 50% confirmed response is legitimately solid. The data came from Memorial Sloan Kettering, which adds credibility. What's interesting is the responses are actually deepening over time, consistent with what they've seen in melanoma and lung cancer applications.

Beyond the sarcoma trial momentum, the financial picture is pretty strong. Q4 revenue hit $87 million, up roughly 30% quarter-over-quarter, driven mainly by Amtagvi uptake. That's their FDA-approved T-cell therapy for solid tumors—the first of its kind—and it's actually gaining traction in the real world. U.S. Amtagvi sales alone were $65 million in Q4, compared to $49 million in the prior year quarter. Full year 2025 they landed $264 million in total product revenue, comfortably within their $250-300 million guidance range.

The sarcoma opportunity looks like it could be meaningful too. They're planning to kick off a registrational trial in Q2 2026 for second-line sarcoma patients and talking to the FDA about expedited pathways. They're also exploring other high-grade sarcoma subtypes, so the addressable market could expand beyond what we're seeing in the pilot data.

Cash position is solid at $303 million, expected to fund operations into Q3 2027, so they've got runway. Pipeline-wise, they've got the lung cancer trial advancing and the global Phase 3 melanoma study ongoing. Stock's trading at $3.63 now after the move, having ranged between $1.64 and $5.88 over the past year. Definitely worth keeping on the radar if you're interested in the cell therapy space.